menu
    • menu
    [{"orgOrder":0,"company":"Vitruvias Therapeutics","sponsor":"PharmaTher","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"CANADA","productType":"Controlled Substance","year":"2023","type":"Collaboration","leadProduct":"Ketamine Hydrochloride","moa":"Glutamate [NMDA] receptor","graph1":"Neurology","graph2":"Phase III","graph3":"Vitruvias Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vitruvias Therapeutics \/ Vitruvias Therapeutics","highestDevelopmentStatusID":"10","companyTruncated":"Vitruvias Therapeutics \/ Vitruvias Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Vitruvias Therapeutics

    Menu

    Vitruvias Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vitruvias Therapeutics

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed

                            Vitruvias Therapeutics

                            U.S.A arrow
                            Biotech Showcase
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Neurology

                            Study Phase : Phase III

                            Recipient : PharmaTher

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PharmaTher and Vitruvias Enter into Collaboration Agreement for Commercialization of KETARX™ (racemic ketami...

                            Details : Under the collaboration, PharmaTher will be responsible for regulatory, manufacturing and supply of Ketarx (ketamine hydrochloride), an FDA-approved NMDA receptor-modulating drug, and Vitruvias will be responsible for the marketing, sales, and distributi...

                            Product Name : Ketarx

                            Product Type : Controlled Substance

                            Upfront Cash : Undisclosed

                            June 20, 2023

                            Lead Product(s) : Ketamine Hydrochloride

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase III

                            Recipient : PharmaTher

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            • Privacy policy
                            • Terms and conditions
                            • Disclaimers
                            • LinkedIn
                            • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.